Lovenox in VTE prevention: The 2009 WSJ article in #msg-38689726 is on-point (as is xrymd’s reply in #msg-38690733). From an investment standpoint, the question is whether the newfound emphasis on averting DVT/PE amounts to material incremental sales or is merely roundoff error in the overall scheme of things.
Related to the other issue, DVT prophylaxis dosing does not require reversal prior to an invasive procedure. At most, you hold the scheduled dose prior to the procedure.
The morning dose has almost always given requiring postponing of the procedure. One of these days a patient will slip through the cracks and I'll have a problem on my hands. I've dodged a few bullets already!
Market Data 
Markets 
AI
